|本期目录/Table of Contents|

[1]陈 炜,周克夫,栗 华*.重组ProTα对肝癌小鼠Treg细胞和NKG2D阳性细胞的影响[J].厦门大学学报(自然科学版),2016,55(03):456-460.[doi:10.6043/j.issn.0438-0479.2016.03.026]
 CHEN Wei,ZHOU Kefu,LI Hua*.Influence of Proportion of Treg Cells and NKG2D-positive Cells by Recombinant ProTα in Mice Bearing Liver Cancer[J].Journal of Xiamen University(Natural Science),2016,55(03):456-460.[doi:10.6043/j.issn.0438-0479.2016.03.026]
点击复制

重组ProTα对肝癌小鼠Treg细胞和NKG2D阳性细胞的影响(PDF)
分享到:

《厦门大学学报(自然科学版)》[ISSN:0438-0479/CN:35-1070/N]

卷:
55卷
期数:
2016年03期
页码:
456-460
栏目:
研究简报
出版日期:
2016-05-25

文章信息/Info

Title:
Influence of Proportion of Treg Cells and NKG2D-positive Cells by Recombinant ProTα in Mice Bearing Liver Cancer
文章编号:
0438-0479(2016)03-0456-05
作者:
陈 炜12周克夫3栗 华2*
1.福建中医药大学研究生院,福建 福州 350108; 2.厦门大学附属第一医院,福建 厦门 361005; 3.厦门大学环境与生态学院,福建 厦门 361102
Author(s):
CHEN Wei12ZHOU Kefu3LI Hua2*
1.Graduate School of Fujian University of Traditional Chinese Medicine,Fuzhou 350108,China; 2.The First Affiliated Hospital of Xiamen University,Xiamen 361005,China; 3.College of the Environment & Ecology, Xiamen University,Xiamen 361102,China
关键词:
重组胸腺素α原 肝癌 调节性T细胞(Treg细胞) NKG2D
Keywords:
recombinant ProTα liver cancer regulatory T cell(Treg cells) NKG2D
分类号:
R 735.7
DOI:
10.6043/j.issn.0438-0479.2016.03.026
文献标志码:
A
摘要:
为观察不同时期应用重组胸腺素α原(ProTα)药物干预下肝癌荷瘤小鼠的抑瘤率,并研究其对Treg细胞和NKG2D阳性细胞的影响,将36只昆明小鼠随机分成空白组、荷瘤组、药物干预组,H22小鼠肝癌细胞皮下移植建立荷瘤小鼠模型,腹腔注射重组ProTα,观察7和14 d后肝癌荷瘤小鼠的抑瘤率,并检测外周单个核细胞中调节性T细胞(Treg细胞)和NKG2D阳性细胞的比例.结果表明:移植瘤7 d后,药物干预组和荷瘤组瘤质量对比无显著差异; 而移植瘤14 d后,药物干预组瘤质量较荷瘤组有显著减小.荷瘤14 d后,荷瘤组较空白组Treg细胞比例升高,NKG2D阳性细胞比例下调,差异显著; 而不论是早期药物干预组还是进展期(即移植瘤7 d后)药物干预组,Treg细胞比例均显著降低,NKG2D阳性细胞显著升高.由此可见,重组ProTα能够抑制肝癌荷瘤小鼠肿瘤生长,且早期、长期用药效果更好,相关作用机制涉及下调Treg细胞数量从而抑制肝癌细胞免疫逃逸,并上调NKG2D阳性细胞数量从而提高其介导的抗肿瘤效应.
Abstract:
To observe the tumor inhibition rate by recombinant ProTα in liver cancer-bearing mice model,and to study the influence of the proportion of Treg cells and NKG2D-positive cells,36 Kunming mice were randomly divided into control group,tumor-bearing group and drug intervention group.Then a tumor-bearing mice model was established by transplanting H22 cells subcutaneously.By medicating recombinant ProTα through intraperitoneal injection,we observed the tumor inhibition rate after 7 days and 14 days,and detected the proportion of Treg cells and NKG2D-positive cells in PBMCs.Results showed that the difference in tumor mass between the tumor-bearing group and the drug intervention group was not significant after bearing tumor for 7 days.However,after bearing tumor for 14 days,the difference in tumor mass was significant.Additionally,the proportion of Treg cells increased and the number of NKG2D-positive cells declined significantly in the tumor-bearing group after bearing tumor for 14 days.No matter 14 days intraperitoneal injection of recombinant ProTα or drug intervention from the advanced stage,the proportion of Treg cells declined and the number of NKG2D-positive cells increased significantly.The results suggest that recombinant ProTα inhibits tumor growing,and the early and long-term drug intervention benefits the most.It is believed that the putative mechanism is related to that recombinant ProTα down-regulates the proportion of Treg cells,inhibiting the immune escape of hepatocellular carcinoma cells,and up-regulates the number of NKG2D-positive cells,improving the NKG2D-mediated anti-tumor effect.

参考文献/References:

[1] SAKAGUCHI S,SAKAGUCHI N,ASANO M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].Journal of Immunology,1995,155(7):3808-3821.
[2] HE Y Q,QIAO B,WEI Y,et al.Foxp3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population[J].Gene,2013,531(2):422-425.
[3] NASROLLAH E,MAHBOOBEH H S,SOMAYEH R,et al.Foxp3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer[J].Iranian Journal of Immunology,2014,11(2):105-112.
[4] WINERDAL M E,PER M,MAX W,et al.Foxp3 and survival in urinary bladder cancer[J].BJU International,2011,108(10):1672-1678.
[5] XU W,LIU H,SONG J,et al.The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer[J].Journal of Cancer Research & Clinical Oncology,2013,139(11):1845-1852.
[6] 张蘋,张利宁,朱法良,等.肝癌荷瘤小鼠调节性T细胞数量的改变及其与肿瘤生长的关系[J].中华肿瘤杂志,2008,29(5):342-345.
[7] KONSTANTINA E,TANER S B,ONFEL B,et al.Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D[J].Journal of Experimental Medicine,2004,199(7):1005-1010.
[8] ANDREAS D,JENNIFER H,MING-YU H,et al.A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity[J].European Journal of Immunology,2003,33(2):381-391.
[9] DIEFENBACH A,JENSEN E R,JAMIESON A M,et al.Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity[J].Nature,2001,413(6852):165-171.
[10] GROH V,WU J,YEE C,et al.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.[J].Nature,2002,419(6908):734-738.
[11] TOMOHIRO O,HIROAKI S,TOSHIAKI Y,et al.Decreased NKG2D expression on CD8+T cell is involved in immune evasion in patients with gastric cancer[J].Clinical Cancer Research,2007,13(21):382-387.
[12] EILERS M S,SCHIRM S,BISHOP J M.The MYC protein activates transcription of the α-prothymosin gene[J].Embo Journal,1991,10(1):133-141.
[13] 郑金来.胸腺素α原研究进展[J].国际免疫学杂志,1998(4):210-214.
[14] 王梅,潘吉勇.胸腺素α原与肿瘤关系的研究进展[J].癌症:英文版,2007,26(3):333-336.
[15] 蔡报伟,栗华,韩伟,等.胸腺素原体内抑制小鼠肝癌细胞H22的研究[J].中国免疫学杂志,2012,28(5):412-414.
[16] 韩伟.重组人胸腺素α原抗肿瘤活性及机理研究[D].厦门:厦门大学,2011:14-25.
[17] 周克夫,厦门伯赛基因转录技术有限公司.胸腺素α原在制备预防和治疗肝癌药物中的应用:中国,CN201210086166.0[P].2012-07-18[2015-12-16].
[18] ZORN E,NELSON E A,MOHSENI M,et al.IL-2 regulates Foxp3 expression in human CD4+CD25+regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo[J].Blood,2006,108(5):1571-1579.
[19] MASSAGUE J,GOMIS R R.The logic of TGF-beta signaling[J].FEBS Lett,2006,580(12):281l-2820.
[20] MAGIS M,WHITESIDE T L.Targeting human inducible regulatory T cells(Tr1)in patients with cancer:blocking of adenosine-prostaglandin E(2)cooperation[J].Expert Opinion on Biological Therapy,2011,11(9):1203-1214.
[21] STRAUSS L,BERGMANN C T.Human circulating CD4+CD25high Foxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis[J].Journal of Immunology,2009,182(3):1469-1480.
[22] ZHANG H H,FEI R,XIE X W,et al.Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients[J].Journal of Peking University(Health Sciences),2009,41(3):313-318.
[23] SHA W H,ZENG X H,MIN L.The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma.[J].Gut Liver,2014,8(3):298-305.
[24] JIANG J H,ZHOU Z F,LI J Y,et al.Expression and significance of the NK cell receptors in primary hepatocellular carcinoma and paracancerous tissues[J].Chinese Journal of Cellular and Molecular Immunology,2012,28(5):529-532.
[25] CLAYTON A,MITCHELL J P,COURT J,et al.Human tumor-derived exosomes down-modulate NKG2D expression[J].Journal of Immunology,2008,180(11):7249-7258.
[26] MATHIAS K,YVONNE D,CLAUDIA W,et al.Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D[J].Journal of Immunology,2008,180(11):7338-7348.
[27] GHIRINGHELLI F,MENARD C,TERME M,et al.CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner[J].Journal of Experimental Medicine,2005,202(8):1075-1085.
[28] SMYTH M J,TENG M W L,JEREMY S,et al.CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer[J].Journal of Immunology,2006,176(3):1582-1587.

备注/Memo

备注/Memo:
收稿日期:2015-12-16 录用日期:2016-02-16
基金项目:福建省自然科学基金(2013J01383); 福建省医学创新课题(2009-CXB-51)
*通信作者:endohlihua@126.com
更新日期/Last Update: 1900-01-01